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| INTRODUC TI ON
Patients with cirrhosis, particularly decompensated cirrhosis, are prone to both bleeding and thrombotic complications.
1 Clotting times are frequently prolonged in cirrhotic patients, but poorly predict procedure-related bleeding in cirrhosis, because these assays are insensitive to coexisting anticoagulant pathway deficiencies seen in cirrhotic patients, such as reduced levels of protein C and antithrombin. 2 Thrombin generation measured by calibrated automated thrombography (CAT) is considered a more accurate representation of an individual's coagulation phenotype. 3 Tissue factor (TF)-stimulated thrombin generation responses can be reduced, normal, or enhanced in cirrhotic patients relative to healthy controls.
In contrast, thrombomodulin modified TF-stimulated thrombin generation responses, a more accurate representation of coagulation status in cirrhosis as it takes into account reduced Protein C levels, range from normal to enhanced responses. [4] [5] [6] [7] These differences in thrombin generation are most apparent in patients with advanced or decompensated cirrhosis.
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It is not known precisely when during the course of cirrhosis progression these changes begin to take place. Understanding the progression of thrombin generation in compensated cirrhosis is important for a variety of reasons. First, coagulation enzymes have been reported to promote fibrosis progression. Many mechanisms have been described including thrombin-mediated activation of stellate cells through protease activated receptors; microthrombi and parenchymal extinction. 8 As a result, anticoagulation may in time be used as a direct therapy for liver fibrosis and cirrhosis. Enoxaparin therapy has been shown to delay the occurrence of decompensation and improve survival in patients with advanced cirrhosis. 9 Second, there is a tendency to avoid anticoagulation for other clinical reasons in patients with cirrhosis due to fears of variceal and nonvariceal hemorrhage. These fears may be misplaced, and a better understanding of hemostasis would help to encourage best practice for other conditions such as stroke and venous thromboembolism. Recent meta-analysis data for anticoagulation and portal vein thrombosis is encouraging for safety.
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Transient elastography (Fibroscan, Echosens) measures the velocity of a shear wave as it passes through the liver to generate a liver stiffness measurement (LSM been shown in meta-analyses to perform well with greater discrimination in predicting decompensation in patients with compensated cirrhosis. 13 We hypothesized that segregating well compensated cirrhotic patients (defined by Child-Pugh, MELD scores, and clotting times)
based on their respective LSMs would allow us to identify patients with early observable differences in parameters of thrombin generation. As such, LSM thresholds were used to separate compensated cirrhotic patients and a cross-sectional analysis of thrombin generation and routine liver function assays were made across LSM groups.
| METHODS

| Patients
Patients were recruited from a single site, prospective cohort study of patients with compensated cirrhosis, over a 2-year period (2013-2015). All patients gave written informed consent.
The study was conducted in line with the Declaration of Helsinki and approved by the Mater Hospital Institutional Review Board.
Inclusion criteria for the cohort study were: a diagnosis of liver cirrhosis by a consistent clinical history and one of the following:
(i) biopsy-proven cirrhosis; (ii) endoscopic or radiological evidence of varices and thrombocytopenia (platelets <150 × 10 9 /L) or radiological evidence of splenomegaly (spleen diameter >11 cm); or (iii) LSM >22.6 kPa for subjects with alcoholic liver disease, LSM >14.6 kPa for subjects with hepatitis C or LSM >17.3 kPa for subjects with all other etiologies of liver disease. Patients who had a previous history of decompensation were compensated for at least 6 months, and decompensation was defined as ascites, encephalopathy, and variceal bleeding. Once patients were enrolled in the cohort study, they were screened for the following exclusion criteria: history of venous thromboembolism, history of portal vein thrombosis, malignancy, the use of anticoagulant or antiplatelet agents, active bacterial infection. Same-day phlebotomy and transient elastography using Fibroscan were performed by a single experienced operator. We used LSM cut-offs previously described in the literature in patients with compensated cirrhosis as being
Essentials
• It is unclear when coagulation abnormalities appear in cirrhotic patients.
• Liver stiffness measurements can be used to stage cirrhosis and are linked to clinical outcomes.
• Liver stiffness measurements are shown to correlate with parameters of thrombin generation.
• It is not dependent on ongoing alcohol use, active HCV infection, or a history of decompensation.
associated with the development of clinically significant portal hypertension (21 kPa) [14] [15] [16] 
| Blood collection
Blood was collected into vacutainers containing 0.106 nmol/L sodium citrate as anticoagulant (10% vol/vol). Platelet poor plasma was prepared by centrifugation of whole blood at 2000 g for 10 minutes.
Plasma was aliquoted and stored at −80°C until analysis.
| Calibrated automated thrombography
Thrombin generation in citrate-anticoagulated platelet-poor plasma was assessed by CAT using a Fluoroskan Ascent Plate ized by measurement of specific parameters, including lag time to initiation of thrombin generation, peak thrombin generated, time to peak thrombin generation, the area under the thrombin generation curve (endogenous thrombin potential, ETP), rate of propagation (or velocity index, calculated as peak thrombin/(time to peak-lagtime), and the rate of attenuation (calculated as peak thrombin/start tailtime to peak). 5 The operator was blinded to patient information until time of data analyses.
| Statistical analysis
Data were analyzed using GraphPad Prism (Horsham, PA). Data were expressed as the mean ± standard deviation or the median ± the in- 
| RESULTS
| Clinical characteristics
| TF-dependent thrombin generation
TF-dependent thrombin generation (1 pmol/L TF, final concentration) was measured in platelet-poor plasma from well-compensated Table S1 .
When cirrhotic patients were grouped in LSM groupings of <21, 21-35, and >35 kPa, there were no significant differences in the lag time to thrombin generation (<21 kPa; 5.7 ± 1.2 minutes, 21-35 kPa;
6.1 ± 2.1 minutes, and >35 kPa; 6.8 ± 2 minutes) ( Figure 1A ). There was also no significant difference in the lag time to thrombin gen- Figure 2B ). Cirrhotic patients with LSM >35 kPa had significantly lower peak thrombin generation values (106 ± 53.7 nmol/L) than patients with LSM <21 kPa (190.4 ± 66.9 nmol/L, P < 0.01, Figure 1C ) and <35 kPa (181.2 ± 64.8 nmol/L, P < 0.01, Figure 2C ).
There was a prolongation in the time to peak thrombin generation when cirrhotic patients with an LSM value >35 kPa (13.1 ± 2.6 minutes, P < 0.05) were compared to patients with LSM values <21 kPa (10.4 ± 2.1 minutes, Figure 1D ) and patients with LSM values <35 kPa (10.68 ± 2.6 minutes, Figure 2D ). As LSM increased, there were significant decreases observed in the rate of propagation (or velocity index). Cirrhotic patients with LSM >35 kPa had lower rates of propagation (19.8 ± 15 nmol/L thrombin/min) relative to cirrhotic patients with LSM <21 kPa (47.5 ± 28.5 nmol/L thrombin/ min, P < 0.05, Figure 1E ) and <35 kPa (44.1 ± 26.6 nmol/L thrombin/min, P < 0.05, Figure 2E ). There was also a significant decrease in the rate of attenuation as LSM increased, suggesting simultaneous decreases in both procoagulant and anticoagulant pathways across LSM groupings. The rate of attenuation was significantly lower in patients with LSM values >35 kPa (5.2 ± 3.3 nmol/L thrombin/min, P < 0.01) and 21-35 kPa (7.5 ± 2.9 nmol/L thrombin/min, P < 0.05) compared to patients with LSM values <21 kPa (11.2 ± 2.6 nmol/L thrombin/min) ( Figure 1F) . Similarly, the rate of (Table 1) . Furthermore, there was no significant correlation between LSM and prothrombin time (r = 0.21, P = 0.1) in the cirrhotic patient cohort.
| DISCUSSION
In this study, we demonstrate that within a cohort of well- rate of propagation and a trend towards a reduced rate of attenuation compared to healthy controls. 5 In our cohort, patients with an LSM < 21 kPa also displayed an increased rate of propagation, while patients with a with an LSM > 35 kPa displayed a significantly reduced rate of attenuation.
As cirrhotic patients also display reduced levels of anticoagulant factors, notably Protein C, many investigators have assessed thrombin generation in the presence of thrombomodulin (a cofactor for thrombin in the activation of Protein C to activated Protein C).
Tripoldi et al observed no significant difference between cirrhotic patients and controls when thrombin generation was measured in the presence of thrombomodulin. 4 Gatt et al demonstrated an increased ETP in the presence of Protac (an nonphysiological activator of Protein C) suggestive of enhanced thrombin generation and a hypercoagulable state. 5 Similarly, Groeneweld et al reported that patients with higher MELDs generated more thrombin in the presence of thrombomodulin. 6 It is highly likely that reductions in plasma protein C levels are present in our patient cohort and would lead to significant differences in thrombin generation responses when measured in presence of thrombomodulin. Thus, the thrombin generation responses reported within for our cohort do not reflect the true coagulation phenotype of our patients. We aim to characterize thrombomodulin-modified thrombin generation in future studies.
In our study, patients with LSM > 35 kPa were characterized by significant reductions in peak thrombin generation, the rate of propagation and rate of attenuation. Transient elastography is now widely available and easy to use and can add further prognostic information to the MELD and Child Pugh Score with regard to the development of decompensation and death. 11 Our data suggest that transient elastography can be used to identify patients at higher risk 
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This study has some important limitations. As previously stated, we did not assess thrombomodulin-modified thrombin generation.
Moreover, the small cohort size and relatively short period of follow-up, precluded an assessment of clinical hemorrhagic or thrombotic events. We plan to undertake future prospective studies in order to address these limitations. We included patients who had a previous episode of decompensation but remained fully compensated for at least 6 months prior to enrolment. Previous work has shown that previous decompensation had no difference on LSM measurement or liver related outcome at 2 years, 21 and in this study we show similar lack of impact.
In conclusion, we demonstrate that patients with wellcompensated cirrhosis (stratified by noninvasive testing) display significant differences in thrombin generation. These differences are evident at an early stage in disease progression prior to any detectable differences in standard laboratory tests such as the prothrombin time. Transient elastography is readily available and is likely to be more widely used in the assessment of early cirrhosis progression in the future. It is possible that changes in thrombin generation in combination with change in liver stiffness over the course of compensated cirrhosis could be explored as clinical marker for impending decompensation.
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